Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFß) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for development of monoclonal antibodies that locally and selectively target the precursor. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Scholar Rock Holding Corporation

Canaccord Genuity analyst Gary Nachman reiterated a Buy rating on Scholar Rock Holding yesterday and set a price target of $62.00. The company’s sh...

Canaccord Genuity Keeps Their Buy Rating on Scholar Rock Holding (SRRK)

J.P. Morgan analyst Tessa Romero maintained a Buy rating on Scholar Rock Holding today and set a price target of $63.00. According to TipRanks, Rom...

J.P. Morgan Keeps Their Buy Rating on Scholar Rock Holding (SRRK)

Scholar Rock Holding (($SRRK)) has held its Q2 earnings call. Read on for the main highlights of the call. Scholar Rock’s latest earnings call stru...

Scholar Rock Readies for Apitegromab Launch Amid Risks

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Progyny (PGNY), Scholar Rock Holding (SRRK) and Asce...

Analysts Offer Insights on Healthcare Companies: Progyny (PGNY), Scholar Rock Holding (SRRK) and Ascendis Pharma (ASND)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on CytomX Therapeutics (CTMX), Cytokinetics (CYTK) and ...

Analysts Offer Insights on Healthcare Companies: CytomX Therapeutics (CTMX), Cytokinetics (CYTK) and Scholar Rock Holding (SRRK)

Bank of America Securities analyst Tazeen Ahmad reiterated a Buy rating on Scholar Rock Holding today and set a price target of $58.00. Ahmad cover...

Scholar Rock Holding (SRRK) Receives a Buy from Bank of America Securities

In a report released today, from Leerink Partners maintained a Buy rating on Scholar Rock Holding, with a price target of $59.00. Currently, the an...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SRRK	$52.52	-1.02%	496.60K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SRRK	$52.52	-1.0%	496.60K
3
4
5
6

SRRK

Get Scholar Rock Holding Corporation Data in Excel

Get Scholar Rock Holding Corporation Data in Excel